OmniAb Explodes 22.8%: OABI Smashes 52-Week Highs as Momentum Ignites

Summary
• OmniAb (OABI) surges 22.77% to $2.75, shattering its 52-week high of $2.795.

• Trading volume spikes to 718,718 shares with a turnover rate of 0.61%, signaling intense institutional and retail interest.

• Technical indicators flash bullish signals with RSI at 60.34 and MACD histogram turning positive at 0.018.

• The biotech stock opened at $2.352 and rallied steadily throughout the session, closing near the day’s peak at $2.75.
Biotech Momentum Drives OmniAb Breakout
OmniAb’s dramatic intraday surge is fueled by a powerful convergence of technical breakout and sector-wide risk-on sentiment. The stock closed at $2.75, up 22.77% from the previous close of $2.24, effectively breaking through its prior 52-week high of $2.795 (intraday high reached $2.795). This move represents a significant deviation from the 200-day moving average of $1.89, indicating a strong shift in momentum. While no specific company news was released, the magnitude of the volume increase to 718,718 shares suggests informed money is positioning ahead of potential catalysts or following broader biotech sector strength.

Biotech Sector Strength Lifts OmniAb
The broader Biotechnology sector is exhibiting robust health, providing a tailwind for high-beta names like OmniAb. Sector leader Vertex Pharmaceuticals (VRTX) is up 1.21% intraday, reflecting a general easing of pressure in the biotech space. This sector-wide appreciation creates a favorable environment for smaller-cap biotechs to outperform, as capital rotates into growth-oriented names with strong technical setups. OmniAb’s 22.77% gain significantly outpaces the sector leader’s modest rise, highlighting its status as a momentum play within the group.

Technical Breakout Strategy & High-Leverage Options Play
The technical landscape for OABI is overwhelmingly bullish, characterized by a short-term and long-term uptrend. Key technical indicators support continued upside potential:
• 200-day Moving Average: $1.89 (Strong Support/Below Price)
• RSI: 60.34 (Bullish Momentum, Not Yet Overbought)
• MACD Histogram: 0.018 (Positive, Indicating Accelerating Upside)
• Bollinger Bands Upper: $2.24 (Price is well above, indicating strong deviation)

OmniAb has decisively broken above its 30-day resistance zone of $2.02–$2.04 and is now testing its all-time highs. The RSI of 60.34 suggests there is still room for growth before the stock enters overbought territory (>70), while the positive MACD histogram confirms that buying pressure is intensifying. Traders should watch for a retest of the $2.795 intraday high; a close above this level could trigger algorithmic buying and further upside. With no leveraged ETFs available for direct OABI exposure, options provide the most efficient vehicle for capturing this momentum.

Based on the provided options chain, we identify two high-conviction plays that balance leverage, liquidity, and volatility:

Option 1: OABI20260821C2.5
• Contract Code: OABI20260821C2.5 (Call Option)
• Strike Price: $2.50
• Expiration: 2026-08-21
• Implied Volatility: 47.37% (Moderate-High, Balanced)
• Leverage Ratio: 10.88%
• Delta: 0.828 (High Sensitivity to Price)
• Theta: -0.008480 (Moderate Time Decay)
• Gamma: 0.976 (High Sensitivity to Delta Change)
• Turnover: 3,270 (High Liquidity)

This contract stands out due to its exceptional liquidity and high delta, meaning it will move almost 1:1 with the underlying stock. The high gamma (0.976) amplifies gains as the stock rises, while the moderate IV (47.37%) avoids the premium costs of extreme volatility. For a 5% upside scenario (Stock Price ~$2.89), the payoff is max(0, 2.89 - 2.50) = $0.39 per share, offering significant percentage returns on the premium paid.

Option 2: OABI20261016C2.5
• Contract Code: OABI20261016C2.5 (Call Option)
• Strike Price: $2.50
• Expiration: 2026-10-16
• Implied Volatility: 68.95% (High, Reflecting Longer Duration Risk)
• Leverage Ratio: 6.04%
• Delta: 0.677 (Moderate-High Sensitivity)
• Theta: -0.003010 (Lower Time Decay than near-term)
• Gamma: 0.434 (Moderate Sensitivity)
• Turnover: 45 (Lower Liquidity)

This longer-dated option offers a lower theta bleed, making it suitable for traders expecting a sustained move rather than an immediate spike. The IV is higher (68.95%), but the longer expiration allows for more time for the thesis to play out. For a 5% upside scenario (Stock Price ~$2.89), the payoff is max(0, 2.89 - 2.50) = $0.39 per share. The lower gamma and theta make it a safer, slower-burning play compared to the August contract.

Aggressive bulls may consider OABI20260821C2.5 for immediate leverage into a breakout above $2.80, while those seeking duration may opt for OABI20261016C2.5.

Bullish Breakout Confirmed: Ride the Momentum
OmniAb’s 22.77% surge is not a fluke but a technical breakout validated by volume and sector strength. The move above the 52-week high of $2.795 opens the door for further gains, supported by a RSI of 60.34 that leaves room for expansion. Investors should monitor the $2.795 resistance level; a sustained hold above this price confirms the breakout. Meanwhile, sector leader Vertex Pharmaceuticals (VRTX) is up 1.21%, reinforcing the biotech sector's positive bias. Watch for a break above $2.80 to confirm continuation or a drop below $2.50 to signal a potential pullback.